SPAGO Share Price Performance
SEK 0.11
-0.13 (-54.56%)
Price SEK 0.11
Share Pricen/a
Spago Nanomedical AB (publ) Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 2 Fair Values set on narratives written by author
SPAGO Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
No trending discussion available.
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Spago Nanomedical AB (publ) Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- -0.033
- -221.30%
- -690.20%
- 0%
About SPAGO
- Founded
- 1999
- Employees
- 6
- CEO
- WebsiteView website
Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well as offers Tumorad (SN201), a radionuclide therapy for treatment of advanced and metastatic cancer, under preclinical development stage. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014. The company was incorporated in 1999 and is based in Lund, Sweden.
